Rigel Pharmaceuticals Inc. (RIGL) expects to report top-line results from a pivotal phase III clinical trial evaluating Fostamatinib in high-risk patients hospitalized with COVID-19 in the fourth quarter of this year.
from RTT - Earnings https://ift.tt/Lx2zcNV
via IFTTT
No comments:
Post a Comment